Brief: FORMYCON AG - ENTERS COOPERATION AGREEMENTS WITH BIOCELYS AND SANTO BIOSIMILAR FOR BIOSIMILAR CANDIDATE
Tue 22:15
BRIEF-FORMYCON AG - ENTERS COOPERATION AGREEMENTS WITH BIOCELYS AND SANTO BIOSIMILAR FOR BIOSIMILAR CANDIDATE Oct 20 (Reuters) - Formycon AG FYB.DE:
EQS-RPT: FORMYCON AG: RELEASE ACCORDING TO ARTICLE 111C OF THE AKTG [THE GERMAN STOCK CORPORATION ACT] WITH THE OBJECTIVE OF EUROPE-WIDE DISTRIBUTION
FORMYCON AG - ENTERS COOPERATION AGREEMENTS WITH BIOCELYS AND SANTO BIOSIMILAR FOR BIOSIMILAR CANDIDATE
FORMYCON AG - AGREEMENT WITH BIOCELYS COVERS DEVELOPMENT, MANUFACTURE, REGULATORY APPROVAL, SUPPLY OF BIOSIMILAR
FORMYCON AG - TO TRANSFER OR PROVIDE RIGHTS AND SERVICES VALUED AT EUR 40–45 MILLION
FORMYCON AG: WILL PARTICIPATE IN FUTURE REVENUES OF SANTO BIOSIMILAR GMBH IN LOW DOUBLE-DIGIT PERCENTAGE SHARE, EXPECTED TO BEGIN IN 2036
Source text: ID:nEQ2ZCD81a
Further company coverage: FYB.DE
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Formycon AG
See all newsBrief: Formycon Says Fyb286 Expands Formycon Biosimilar Pipeline Targeting Niche Indication
Brief: FORMYCON AG - ENTERS COOPERATION AGREEMENTS WITH BIOCELYS AND SANTO BIOSIMILAR FOR BIOSIMILAR CANDIDATE
Brief: Formycon And Zydus Say FYB206 Becomes First Publicly Announced Keytruda Biosimilar Accepted For Review By FDA
Brief: Formycon AG - Clinical Development Of FYB206 Completed In July 2026
Formycon H1 revenue rises sharply on milestone payments, EBITDA loss narrows